UCB NORDIC A/S: Financial statements 2015
CVR: 26688949
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 33,732,000 and a net result of DKK 2,102,000 compared with DKK 2,681,000 the year before. That is an increase of 0.6% compared with the year before. Equity in the 2015 report amounted to DKK 8,203,000. The solvency ratio was 8.5%.
- Gross Profit
- DKK 33,732,000
- Profit/Loss
- DKK 2,102,000
- Equity
- DKK 8,203,000
- Total Assets
- DKK 96,156,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 33.7M | 2.1M | 8.2M | - |
| 2014 | - | 33.5M | 2.7M | 8.8M | - |
| 2013 | - | 28.9M | 403K | 6.5M | 26 |
| 2012 | - | 31.5M | -1.3M | 6.1M | 26 |
Official annual report
How creditworthy is UCB NORDIC A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of December 1, 2015, Mohammed Nazir Khoso Baluch has left the board of directors of UCB NORDIC A/S.
UCB NORDIC A/S has published its annual report for 2014. Gross profit came to DKK 33,544,000, and the net result was DKK 2,681,000.
As of June 18, 2015, Yogesh Naranbhai Khatri has joined the board of directors of UCB NORDIC A/S.
As of June 18, 2015, Frantisek Rozdalovsky has left the board of directors of UCB NORDIC A/S.
About UCB NORDIC A/S
UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.